Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Study of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions
- Conditions
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 391
- Registration Number
- NCT02626793
- Locations
- 🇩🇪
Gertraud Krähn-Senftleben, Blaubeuren, Baden-Württemberg, Germany
🇩🇪Clarissa Allmacher, Hersbruck, Bayern, Germany
🇩🇪Ildiko Sugar-Bunk, Krumbach, Bayern, Germany
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 86
- Registration Number
- NCT02593773
- Locations
- 🇺🇸
University of Florida - Clinical Research Center, Gainesville, Florida, United States
🇺🇸University of Iowa Children's Hospital, Iowa City, Iowa, United States
🇺🇸University of California, Los Angeles Neurology Clinic, Los Angeles, California, United States
Open-label Study Using 50 Mg Liquid Etanercept Subcutaneous Injection in the Thigh to Compare an Auto-injector Device and a Manual Injection in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 36
- Registration Number
- NCT02588534
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 92
- Registration Number
- NCT02415127
- Locations
- 🇺🇸
University of Iowa Children's Hospital, Iowa City, Iowa, United States
🇺🇸University of California, Los Angeles Neurology Clinic, Los Angeles, California, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma
- Conditions
- Interventions
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 112
- Registration Number
- NCT02366195
- Locations
- 🇬🇧
Research Site, Wirral, United Kingdom
A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Amgen
- Target Recruit Count
- 51
- Registration Number
- NCT02348879
Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR
- Conditions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 218
- Registration Number
- NCT02322736
- Locations
- 🇬🇷
Research Site, Thessaloniki, Greece
Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma
- Conditions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- Amgen
- Registration Number
- NCT02297529
- Locations
- 🇨🇭
Research Site, Zürich, Switzerland
A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 75
- Registration Number
- NCT02287610
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
- Conditions
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- Amgen
- Registration Number
- NCT02147951
- Locations
- 🇺🇸
Research Site, Wauwatosa, Wisconsin, United States